180 related articles for article (PubMed ID: 15758578)
1. [Aberrant promoter methylation of tumor suppressor genes in serum from lung cancer patients: frequency and correlation with clinicopathological characteristics].
Zemaitis M; Rieger N; Fischer JR; Sakalauskas R; Malakauskas K; Lahm H
Medicina (Kaunas); 2005; 41(2):123-31. PubMed ID: 15758578
[TBL] [Abstract][Full Text] [Related]
2. Aberrant promoter hypermethylation in serum DNA from patients with silicosis.
Umemura S; Fujimoto N; Hiraki A; Gemba K; Takigawa N; Fujiwara K; Fujii M; Umemura H; Satoh M; Tabata M; Ueoka H; Kiura K; Kishimoto T; Tanimoto M
Carcinogenesis; 2008 Sep; 29(9):1845-9. PubMed ID: 18632757
[TBL] [Abstract][Full Text] [Related]
3. Aberrant promoter methylation of multiple genes in non-small cell lung cancers.
Zöchbauer-Müller S; Fong KM; Virmani AK; Geradts J; Gazdar AF; Minna JD
Cancer Res; 2001 Jan; 61(1):249-55. PubMed ID: 11196170
[TBL] [Abstract][Full Text] [Related]
4. Hypermethylation of FHIT as a prognostic marker in nonsmall cell lung carcinoma.
Maruyama R; Sugio K; Yoshino I; Maehara Y; Gazdar AF
Cancer; 2004 Apr; 100(7):1472-7. PubMed ID: 15042681
[TBL] [Abstract][Full Text] [Related]
5. Detection of aberrant promoter hypermethylation of tumor suppressor genes in serum DNA from non-small cell lung cancer patients.
Esteller M; Sanchez-Cespedes M; Rosell R; Sidransky D; Baylin SB; Herman JG
Cancer Res; 1999 Jan; 59(1):67-70. PubMed ID: 9892187
[TBL] [Abstract][Full Text] [Related]
6. DNA methylation profiles of lung tumors.
Toyooka S; Toyooka KO; Maruyama R; Virmani AK; Girard L; Miyajima K; Harada K; Ariyoshi Y; Takahashi T; Sugio K; Brambilla E; Gilcrease M; Minna JD; Gazdar AF
Mol Cancer Ther; 2001 Nov; 1(1):61-7. PubMed ID: 12467239
[TBL] [Abstract][Full Text] [Related]
7. Aberrant promoter methylation profile in pleural fluid DNA and clinicopathological factors in patients with non-small cell lung cancer.
Katayama H; Hiraki A; Fujiwara K; Matsuo K; Maeda T; Chikamori K; Kishino D; Tajima K; Ueoka H; Aoe K
Asian Pac J Cancer Prev; 2007; 8(2):221-4. PubMed ID: 17696735
[TBL] [Abstract][Full Text] [Related]
8. Aberrant methylation of the adenomatous polyposis coli (APC) gene promoter 1A in breast and lung carcinomas.
Virmani AK; Rathi A; Sathyanarayana UG; Padar A; Huang CX; Cunnigham HT; Farinas AJ; Milchgrub S; Euhus DM; Gilcrease M; Herman J; Minna JD; Gazdar AF
Clin Cancer Res; 2001 Jul; 7(7):1998-2004. PubMed ID: 11448917
[TBL] [Abstract][Full Text] [Related]
9. Tumor suppressor gene promoter hypermethylation in serum of breast cancer patients.
Dulaimi E; Hillinck J; Ibanez de Caceres I; Al-Saleem T; Cairns P
Clin Cancer Res; 2004 Sep; 10(18 Pt 1):6189-93. PubMed ID: 15448006
[TBL] [Abstract][Full Text] [Related]
10. Methylation profile of the promoter CpG islands of 31 genes that may contribute to colorectal carcinogenesis.
Xu XL; Yu J; Zhang HY; Sun MH; Gu J; Du X; Shi DR; Wang P; Yang ZH; Zhu JD
World J Gastroenterol; 2004 Dec; 10(23):3441-54. PubMed ID: 15526363
[TBL] [Abstract][Full Text] [Related]
11. Quantitative adenomatous polyposis coli promoter methylation analysis in tumor tissue, serum, and plasma DNA of patients with lung cancer.
Usadel H; Brabender J; Danenberg KD; Jerónimo C; Harden S; Engles J; Danenberg PV; Yang S; Sidransky D
Cancer Res; 2002 Jan; 62(2):371-5. PubMed ID: 11809682
[TBL] [Abstract][Full Text] [Related]
12. Gene methylation in gastric cancer.
Qu Y; Dang S; Hou P
Clin Chim Acta; 2013 Sep; 424():53-65. PubMed ID: 23669186
[TBL] [Abstract][Full Text] [Related]
13. Identification of epigenetic aberrant promoter methylation in serum DNA is useful for early detection of lung cancer.
Fujiwara K; Fujimoto N; Tabata M; Nishii K; Matsuo K; Hotta K; Kozuki T; Aoe M; Kiura K; Ueoka H; Tanimoto M
Clin Cancer Res; 2005 Feb; 11(3):1219-25. PubMed ID: 15709192
[TBL] [Abstract][Full Text] [Related]
14. Multiple gene methylation of nonsmall cell lung cancers evaluated with 3-dimensional microarray.
Wang Y; Zhang D; Zheng W; Luo J; Bai Y; Lu Z
Cancer; 2008 Mar; 112(6):1325-36. PubMed ID: 18286531
[TBL] [Abstract][Full Text] [Related]
15. Characterization of a multiple epigenetic marker panel for lung cancer detection and risk assessment in plasma.
Hsu HS; Chen TP; Hung CH; Wen CK; Lin RK; Lee HC; Wang YC
Cancer; 2007 Nov; 110(9):2019-26. PubMed ID: 17876837
[TBL] [Abstract][Full Text] [Related]
16. Tumor-specific methylation in bronchial lavage for the early detection of non-small-cell lung cancer.
Kim H; Kwon YM; Kim JS; Lee H; Park JH; Shim YM; Han J; Park J; Kim DH
J Clin Oncol; 2004 Jun; 22(12):2363-70. PubMed ID: 15197197
[TBL] [Abstract][Full Text] [Related]
17. Clinicopathological significance of aberrant methylation of RARbeta2 at 3p24, RASSF1A at 3p21.3, and FHIT at 3p14.2 in patients with non-small cell lung cancer.
Tomizawa Y; Iijima H; Nomoto T; Iwasaki Y; Otani Y; Tsuchiya S; Saito R; Dobashi K; Nakajima T; Mori M
Lung Cancer; 2004 Dec; 46(3):305-12. PubMed ID: 15541815
[TBL] [Abstract][Full Text] [Related]
18. Smoke exposure, histologic type and geography-related differences in the methylation profiles of non-small cell lung cancer.
Toyooka S; Maruyama R; Toyooka KO; McLerran D; Feng Z; Fukuyama Y; Virmani AK; Zochbauer-Muller S; Tsukuda K; Sugio K; Shimizu N; Shimizu K; Lee H; Chen CY; Fong KM; Gilcrease M; Roth JA; Minna JD; Gazdar AF
Int J Cancer; 2003 Jan; 103(2):153-60. PubMed ID: 12455028
[TBL] [Abstract][Full Text] [Related]
19. Aberrant promoter methylation in bronchial epithelium and sputum from current and former smokers.
Belinsky SA; Palmisano WA; Gilliland FD; Crooks LA; Divine KK; Winters SA; Grimes MJ; Harms HJ; Tellez CS; Smith TM; Moots PP; Lechner JF; Stidley CA; Crowell RE
Cancer Res; 2002 Apr; 62(8):2370-7. PubMed ID: 11956099
[TBL] [Abstract][Full Text] [Related]
20. Aberrant p16 promoter methylation in smokers and former smokers with nonsmall cell lung cancer.
Jarmalaite S; Kannio A; Anttila S; Lazutka JR; Husgafvel-Pursiainen K
Int J Cancer; 2003 Oct; 106(6):913-8. PubMed ID: 12918069
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
